Essex Investment Management Co. LLC Buys 96,639 Shares of AngioDynamics, Inc. $ANGO

Essex Investment Management Co. LLC boosted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 41.9% during the third quarter, HoldingsChannel reports. The firm owned 327,396 shares of the medical instruments supplier’s stock after buying an additional 96,639 shares during the period. Essex Investment Management Co. LLC’s holdings in AngioDynamics were worth $3,657,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. State of Alaska Department of Revenue purchased a new stake in shares of AngioDynamics during the 3rd quarter valued at $25,000. State of Wyoming purchased a new position in AngioDynamics in the second quarter worth $31,000. Tower Research Capital LLC TRC increased its stake in AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 4,268 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in AngioDynamics during the second quarter valued at about $90,000. Finally, Legal & General Group Plc lifted its stake in AngioDynamics by 279.5% during the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after purchasing an additional 9,098 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Up 1.0%

Shares of NASDAQ ANGO opened at $10.67 on Tuesday. The firm’s fifty day moving average is $11.82 and its 200 day moving average is $11.17. AngioDynamics, Inc. has a 52 week low of $8.27 and a 52 week high of $13.99. The company has a market cap of $439.82 million, a price-to-earnings ratio of -15.93 and a beta of 0.52.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.